EA014076B1 - Применение рибозы-цистеина для лечения гипоксии - Google Patents
Применение рибозы-цистеина для лечения гипоксии Download PDFInfo
- Publication number
- EA014076B1 EA014076B1 EA200701017A EA200701017A EA014076B1 EA 014076 B1 EA014076 B1 EA 014076B1 EA 200701017 A EA200701017 A EA 200701017A EA 200701017 A EA200701017 A EA 200701017A EA 014076 B1 EA014076 B1 EA 014076B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hypoxia
- caused
- tissue
- administered
- levels
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 39
- 230000007954 hypoxia Effects 0.000 title claims abstract description 23
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 32
- 229960003180 glutathione Drugs 0.000 claims abstract description 16
- 108010024636 Glutathione Proteins 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 30
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 27
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 22
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 22
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 22
- 230000001146 hypoxic effect Effects 0.000 claims description 16
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 15
- 235000018417 cysteine Nutrition 0.000 claims description 15
- 208000028867 ischemia Diseases 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 208000017667 Chronic Disease Diseases 0.000 claims description 7
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 206010002091 Anaesthesia Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 230000037005 anaesthesia Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 230000005980 lung dysfunction Effects 0.000 claims 2
- 208000002089 myocardial stunning Diseases 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 10
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 9
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- KJQFBVYMGADDTQ-UHFFFAOYSA-N S-butyl-DL-homocysteine (S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000004201 L-cysteine Substances 0.000 description 6
- 235000013878 L-cysteine Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- LAXXPOJCFVMVAX-UHFFFAOYSA-N 2-azaniumyl-4-butylsulfanylbutanoate Chemical compound CCCCSCCC(N)C(O)=O LAXXPOJCFVMVAX-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 101100301148 Arabidopsis thaliana RCCR gene Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QSZRHMZKUUXBNB-LOLRQIBTSA-N (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid 5-[(3-carboxy-4-nitrophenyl)disulfanyl]-2-nitrobenzoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 QSZRHMZKUUXBNB-LOLRQIBTSA-N 0.000 description 1
- BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241001070184 Edenia Species 0.000 description 1
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101150092727 KLF10 gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/990,933 US20060105972A1 (en) | 2004-11-17 | 2004-11-17 | Method to enhance delivery of glutathione and ATP levels in cells |
| PCT/US2005/041458 WO2006055597A1 (en) | 2004-11-17 | 2005-11-16 | Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200701017A1 EA200701017A1 (ru) | 2007-10-26 |
| EA014076B1 true EA014076B1 (ru) | 2010-08-30 |
Family
ID=35759146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200701017A EA014076B1 (ru) | 2004-11-17 | 2005-11-16 | Применение рибозы-цистеина для лечения гипоксии |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20060105972A1 (enExample) |
| EP (1) | EP1824481B1 (enExample) |
| JP (1) | JP2008520681A (enExample) |
| KR (1) | KR20070095900A (enExample) |
| CN (1) | CN101060840A (enExample) |
| AU (1) | AU2005307885B2 (enExample) |
| BR (1) | BRPI0516814A (enExample) |
| CA (1) | CA2587616C (enExample) |
| DK (1) | DK1824481T3 (enExample) |
| EA (1) | EA014076B1 (enExample) |
| ES (1) | ES2390228T3 (enExample) |
| MX (1) | MX2007005835A (enExample) |
| PL (1) | PL1824481T3 (enExample) |
| WO (1) | WO2006055597A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2751945C2 (ru) * | 2015-05-22 | 2021-07-21 | Зе А2 Милк Компани Лимитед | Бета-казеин а2 и антиоксидантная способность |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060105972A1 (en) | 2004-11-17 | 2006-05-18 | Nagasawa Herbert T | Method to enhance delivery of glutathione and ATP levels in cells |
| JP4982755B2 (ja) * | 2006-06-27 | 2012-07-25 | 国立大学法人 長崎大学 | 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法 |
| US8685951B2 (en) | 2007-03-27 | 2014-04-01 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for cytoprotection |
| US20100055206A1 (en) * | 2008-04-02 | 2010-03-04 | St Cyr John A | Use of ribose in first response to acute myocardial infarction |
| TW201202209A (en) * | 2010-01-28 | 2012-01-16 | Max International Llc | Methods of preparing thiazolidines |
| TW201201712A (en) * | 2010-01-28 | 2012-01-16 | Max International Llc | Compositions comprising sugar-cysteine products |
| US20110287109A1 (en) * | 2010-05-24 | 2011-11-24 | Max International, Llc | Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products |
| CA2843388A1 (en) * | 2011-07-27 | 2013-01-31 | Max International, Llc | Compositions comprising sugar-cysteine products |
| US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0257992A2 (en) * | 1986-08-20 | 1988-03-02 | Yamanouchi Pharmaceutical Co. Ltd. | Prophylactic and therapeutic agents for cerebral ischemia |
| US6218366B1 (en) * | 1998-06-19 | 2001-04-17 | Bioenergy, Inc. | Method for raising the hypoxic threshold |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1120033B (it) | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| US4647571A (en) | 1981-02-11 | 1987-03-03 | Cornell Research Foundation | Cysteine delivery composition |
| US4335210A (en) * | 1981-02-11 | 1982-06-15 | Cornell Research Foundation | Method of producing L-cysteine |
| US4605644A (en) * | 1985-02-07 | 1986-08-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia employing ribose and adenine |
| US4719201A (en) * | 1985-02-07 | 1988-01-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia |
| US4736060A (en) | 1985-08-06 | 1988-04-05 | Nippon Rikagakuyakuhin Co., Ltd. | Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine |
| US4868114A (en) * | 1987-08-05 | 1989-09-19 | Regents Of The University Of Minnesota | Method for elevating glutathione levels |
| US5095027A (en) * | 1991-02-28 | 1992-03-10 | Clintec Nutrition Co. | Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid |
| JP2873089B2 (ja) * | 1991-04-15 | 1999-03-24 | 帝人株式会社 | 虚血・再灌流組織障害及び不整脈並びに活性酸素・フリーラジカルによる肺障害の予防又は治療剤 |
| US5631234A (en) * | 1991-04-15 | 1997-05-20 | Teijin Limited | Method for treating ischemia-reperfusion tissue injury |
| US5292538A (en) | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
| JPH10139665A (ja) * | 1996-09-12 | 1998-05-26 | Sankyo Co Ltd | トログリタゾンを含有するグルタチオン還元酵素活性増強剤 |
| CA2280093A1 (en) | 1997-02-04 | 1998-08-06 | John V. Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
| US6730336B2 (en) | 1998-01-30 | 2004-05-04 | The Procter & Gamble Co. | Fortified beverages with improved texture and flavor impact at lower dosage of solids |
| US7153503B1 (en) | 1998-12-19 | 2006-12-26 | Janeel Henderson | Comprehensive dietary supplement |
| US6534480B2 (en) * | 1999-06-17 | 2003-03-18 | Bioenergy Inc. | Compositions for increasing energy in vivo |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| US6881425B2 (en) | 2001-08-31 | 2005-04-19 | Council Of Scientific And Industrial Research | Custom made herbal health promotive formulation for females/expectant mothers |
| US6572899B1 (en) | 2002-07-03 | 2003-06-03 | Vitacost.Com, Inc. | Memory loss treatment formulation |
| US7455857B2 (en) | 2003-04-08 | 2008-11-25 | Janeel Henderson | Energy generating composition |
| GB0319463D0 (en) | 2003-08-20 | 2003-09-17 | Givaudan Sa | Compounds |
| US20050100537A1 (en) | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
| US20060105972A1 (en) | 2004-11-17 | 2006-05-18 | Nagasawa Herbert T | Method to enhance delivery of glutathione and ATP levels in cells |
| US8962058B2 (en) | 2005-11-23 | 2015-02-24 | The Coca-Cola Company | High-potency sweetener composition with antioxidant and compositions sweetened therewith |
| NZ594596A (en) | 2006-02-10 | 2011-10-28 | Mannatech Inc | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
| US8685951B2 (en) | 2007-03-27 | 2014-04-01 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for cytoprotection |
| US20100074969A1 (en) | 2008-09-19 | 2010-03-25 | Unicity International, Inc. | Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix |
| TW201201712A (en) | 2010-01-28 | 2012-01-16 | Max International Llc | Compositions comprising sugar-cysteine products |
| US20110287109A1 (en) | 2010-05-24 | 2011-11-24 | Max International, Llc | Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products |
-
2004
- 2004-11-17 US US10/990,933 patent/US20060105972A1/en not_active Abandoned
-
2005
- 2005-11-16 CA CA2587616A patent/CA2587616C/en not_active Expired - Fee Related
- 2005-11-16 JP JP2007543186A patent/JP2008520681A/ja active Pending
- 2005-11-16 ES ES05823154T patent/ES2390228T3/es not_active Expired - Lifetime
- 2005-11-16 KR KR1020077013535A patent/KR20070095900A/ko not_active Ceased
- 2005-11-16 BR BRPI0516814-7A patent/BRPI0516814A/pt not_active IP Right Cessation
- 2005-11-16 DK DK05823154.9T patent/DK1824481T3/da active
- 2005-11-16 EA EA200701017A patent/EA014076B1/ru not_active IP Right Cessation
- 2005-11-16 WO PCT/US2005/041458 patent/WO2006055597A1/en not_active Ceased
- 2005-11-16 PL PL05823154T patent/PL1824481T3/pl unknown
- 2005-11-16 CN CNA2005800393226A patent/CN101060840A/zh active Pending
- 2005-11-16 EP EP05823154A patent/EP1824481B1/en not_active Expired - Lifetime
- 2005-11-16 MX MX2007005835A patent/MX2007005835A/es unknown
- 2005-11-16 AU AU2005307885A patent/AU2005307885B2/en not_active Ceased
-
2008
- 2008-07-30 US US12/182,354 patent/US8501700B2/en active Active
-
2013
- 2013-08-02 US US13/958,530 patent/US9144570B2/en not_active Expired - Lifetime
-
2015
- 2015-08-27 US US14/838,274 patent/US20160082029A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0257992A2 (en) * | 1986-08-20 | 1988-03-02 | Yamanouchi Pharmaceutical Co. Ltd. | Prophylactic and therapeutic agents for cerebral ischemia |
| US6218366B1 (en) * | 1998-06-19 | 2001-04-17 | Bioenergy, Inc. | Method for raising the hypoxic threshold |
Non-Patent Citations (2)
| Title |
|---|
| ROBERTS J .C. ET AL.: "TIME COURSE FOR THE ELEVATION OF GLUTATHIONE IN NUMEROUS ORGANS OF L1210-BEARING CDF1 MICE GIVEN THE L CYSTEINE PRODRUG RIBCYS", TOXICOLOGY LETTERS (SHANNON), vol. 59, no. 1-3, 1991, pages 245-252, XP002369286, ISSN: 0378-4274, cited in the application, the whole document * |
| ROBERTS J. C. ET AL.: "PRODRUGS OF L-CYSTEINE AS PROTECTIVE AGENTS AGAINST ACETAMINOPHEN-INDUCED HAPATOTOXICITY, 2-(POLYHYDROXYALKYL)- AND 2-(POLYACETOXYALKYL)THIAZOLIDINE-4(R)-CARB OXYLIC ACIDS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 30, 1987, pages 1891-1896, XP001019184, ISSN: 0022-2623, abstract, page 1893, column 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2751945C2 (ru) * | 2015-05-22 | 2021-07-21 | Зе А2 Милк Компани Лимитед | Бета-казеин а2 и антиоксидантная способность |
| RU2751945C9 (ru) * | 2015-05-22 | 2021-12-21 | Зе А2 Милк Компани Лимитед | Бета-казеин а2 и антиоксидантная способность |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070095900A (ko) | 2007-10-01 |
| AU2005307885A2 (en) | 2006-05-26 |
| JP2008520681A (ja) | 2008-06-19 |
| ES2390228T3 (es) | 2012-11-07 |
| US20060105972A1 (en) | 2006-05-18 |
| EA200701017A1 (ru) | 2007-10-26 |
| CA2587616C (en) | 2015-03-17 |
| US8501700B2 (en) | 2013-08-06 |
| AU2005307885A1 (en) | 2006-05-26 |
| CN101060840A (zh) | 2007-10-24 |
| PL1824481T3 (pl) | 2012-11-30 |
| US20160082029A1 (en) | 2016-03-24 |
| EP1824481A1 (en) | 2007-08-29 |
| US20090042822A1 (en) | 2009-02-12 |
| US9144570B2 (en) | 2015-09-29 |
| CA2587616A1 (en) | 2006-05-26 |
| US20130317072A1 (en) | 2013-11-28 |
| DK1824481T3 (da) | 2012-09-24 |
| EP1824481B1 (en) | 2012-08-29 |
| AU2005307885B2 (en) | 2010-12-23 |
| WO2006055597A1 (en) | 2006-05-26 |
| BRPI0516814A (pt) | 2008-09-23 |
| MX2007005835A (es) | 2007-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9144570B2 (en) | Method to enhance delivery of glutathione and ATP levels in cells | |
| US6075031A (en) | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders | |
| US20110245312A1 (en) | Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function | |
| KR20140121490A (ko) | ５-아미노레불린산 또는 그 유도체를 유효성분으로 하는 항말라리아약 | |
| CA2091766C (en) | Enhancement of glutathione levels with glutamine | |
| TW201412306A (zh) | 流感病毒傳染病之預防治療劑 | |
| US20180125805A1 (en) | Prophylactic/therapeutic agent for virus infections which comprises ala compound | |
| US5712259A (en) | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome | |
| EP1014808B1 (en) | Fatty acids as a diet supplement | |
| US11253495B2 (en) | Pharmaceutical composition for treating excessive lactate production and acidemia | |
| CN104415023A (zh) | 预防或/和治疗胰岛素抵抗及相关病症的组合物 | |
| RU2096034C1 (ru) | Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием | |
| ES2271265T3 (es) | Utilizacion de mangafodipir en el tratamiento de insuficiencia hepatocelular. | |
| JP6709476B1 (ja) | シトリン欠損症治療剤 | |
| HK1114501A (en) | Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells | |
| RU2169568C2 (ru) | Средство для коррекции энергетического обмена | |
| WO2008040208A1 (fr) | (2z)-2-(3,4-dihydroxybenzylidene)-1-benzofuran-3(2h)-one utilisé pour la fabrication de médicaments destinés au traitement de cancers | |
| BR112021002855B1 (pt) | Usos de pelo menos uma glicina ou de um derivado da mesma, de pelo menos uma n-acetilcisteína ou de um derivado da mesma e de pelo menos um ribosídeo de nicotinamida ou de um precursor de nad+ , composições compreendendo os mesmos, e kit | |
| Plante | Excretion of Uric Acid in Man and the Dog | |
| CZ20003831A3 (cs) | Přípravek obsahující L-karnitin nebo alkanoyl Lkarnitinu a NADH a/nebo NADPH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |